Outcomes and estimation
ARI, postoperative infections, implant failure
COMPLICATIONS, POSTOPERATIVE INFECTION
Overall, two implant failures occurred in participants treated with clindamycin (RR: not estimable, ARI = 0.06; CI: − 0.03–0.16, NNH = 15.5; and CI: 6–∞). The ARI indicated that 6% of the patients would experience implant failure under clindamycin treatment and would not have received placebo. The NNH predicted that for every 15 participants treated with clindamycin, one implant failure would occur beyond those that would have happened under placebo treatment. Nevertheless, there were no significant differences between the groups (Three patients suffered postoperative infections, and two of them were administered rescue antibiotic treatment. By contrast, the remaining patient did not receive the rescue antibiotic owing to implant failure and removal. Both participants who received the rescue antibiotic belonged to the control group, whereas the participant with implant failure belonged to the clindamycin group (RR: 0.5; CI: 0.05–5.23, ARR = 0.03; CI: − 0.07–0.13, NNT = 31; and CI: 7.2–∞). The ARR suggested that 3.2% of the patients would not experience postoperative infections under clindamycin treatment, which they would experience under placebo. The NNT indicated that 31 patients would need to be treated with clindamycin to prevent one patient from suffering a postoperative infection. However, there were no significant differences between the groups (Considering the occurrence of postoperative infections or oral implant failures per participant as the overall complications, there were two participants in each treatment group with complications (RR = 1; CI: 0.15–6.66, ARR = 0; CI: − 0.12–0.12, NNT: not estimable, and 